7. Summary of Safety and Effectiveness

"510(K) SUMMARY"

Submitted By: Dr. Manfred Mäder
Senior Vice President
Quality Management & Regulatory Affairs
Ypsomed AG

Date Prepared: April 26, 2010

7.1 Trade/Proprietary Name: Clickfine Pen Needle

7.2 Common/Usual Name: Injection Pen Needle

7.3 Classification Name: Hypodermic single lumen needle

7.4 Classification: FDA has classified Hypodermic single lumen needles in Class II. Final Order was published in the Federal Register on October 21, 1980 after review by the General Hospital and Personal Use Devices Classification Panel.

Panel: 80 Procode: FMI

7.5 Purpose of Submission: To establish the substantial equivalence of the modified Ypsomed Clickfine Pen Needles to the currently marketed Disetronic Penfine Insulin Injection Pen Needles.

Substantial Equivalence: The Ypsomed Clickfine Pen Needles are substantially equivalent to the Disetronic Penfine Insulin Injection Pen Needles (K013782). The equivalence is supported by the attached documentation.

7.6 Device Description

The Ypsomed Clickfine Pen Needles are sterile, non-pyrogenic, single use needles designed to be used with commercially available pen-injectors for insulin administration. Each needle is individually packaged in a sealed protective container with peel tab. The pen needles are used by peeling back the peel tab and snapping the hub onto the threaded end of the pen injector. The back end of the cannula punctures the rubber injection port of the drug reservoir in the pen-injector. The outer protective cap is then removed. The inner protective cap will remain over the needle until the insulin is ready to be injected. When the injection is needed, the inner protective cap is removed and the needle is inserted into the chosen site. The pen-injector automatically delivers the insulin through the needle. The protective cap is replaced and the needle is then removed, safely discarded and replaced with a new needle.
7.7 Intended Use
The intended use of the modified device remains the same as the predicate device (Disetronic Penfine Insulin Injection Pen Needles, K013782):
The Ypsomed Clickfine Pen Needles are intended for the hypodermic injection of insulin into the body when attached to an injection pen.

7.8 Technological Characteristics
The technological characteristics have not changed.

7.9 Performance and Safety Data
Ypsomed has performed the relevant assessments specified in the following international and internal standards and protocols and confirmed compliance of the modified devices and equivalence to the predicate devices.
The Clickfine Pen Needles have met the requirements of the relevant sections of the following standards:
• ISO 9626:1991/Amd.1:2001 Stainless steel needle tubing for the manufacture of medical devices
• ISO 7864:1993 Sterile hypodermic needles for single use
• ISO 10993-1:2003 Biological evaluation of medical devices – Part 1: Evaluation and testing
• Puncture resistance of outer cap – Equivalent to Unmodified Device
• Seal Integrity of Sterile barrier – Equivalent to Unmodified Device

The verifications have shown evidence that the Clickfine Pen Needles meet the acceptance criteria of these standards. Based on the results it can be concluded that the device performance and safety are acceptable for the product.

7.10 Conclusion
Ypsomed AG concludes based on the information presented that the modified product is substantially equivalent to the current product legally marketed in the USA.
Dr. Manfred Mader  
Senior Vice President  
YPSomEd AG  
Brunnmattstrasse 6  
Burgdorf, Switzerland CH-3401

Re: K100436  
Trade/Device Name: Clickfine Pen Needle  
Regulation Number: 21 CFR 880.5570  
Regulation Name: Hypodermic Single Lumen Needle  
Regulatory Class: II  
Product Code: FMI  
Dated: March 26, 2010  
Received: April 1, 2010

Dear Dr. Manfred Mader:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance. Also, please note the regulation entitled, “Misbranding by reference to premarket notification” (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Anthony D. Watson, B.S., M.S., M.B.A.
Director
Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure
Indications for Use

510(k) Number (if known):

Device Name: Clickfine Pen Needle

Indications For Use: The Clickfine pen needle is intended for the hypodermic injection of insulin into the body when attached to a pen-injector.

Prescription Use ______ AND/OR Over-The-Counter Use X
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Signature

Division Sign-Off
Division of Anesthesiology, General Hospital
Infection Control, Dental Devices

510(k) Number: K100436